复星医药子公司与Expedition签署许可协议

Core Insights - Fosun Pharma announced a licensing agreement with Expedition for the development, production, and commercialization of the investigational product XH-S004 outside of China and Hong Kong [2] - XH-S004 is a small molecule oral DPP-1 inhibitor that aims to reduce inflammation and block the cycle of infection and airway structural damage [2] - Potential indications for XH-S004 include non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease [2] Financial Terms - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments related to development and regulatory achievements [2] - Additionally, Expedition may pay up to $525 million in sales milestone payments based on annual net sales of the licensed product in the licensed territory [2]